We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Elevated Fructosamine Levels Associated with Increased PJI Risk

By LabMedica International staff writers
Posted on 24 Nov 2020
Print article
Image: Elevated fructosamine levels were associated with increased periprosthetic joint infection risk (Photo courtesy of Kristine Houck, MA).
Image: Elevated fructosamine levels were associated with increased periprosthetic joint infection risk (Photo courtesy of Kristine Houck, MA).
Periprosthetic joint infection (PJI) is the most serious complication that lowers the quality of patients’ life by elevating the patients’ burden of cost and affecting the outcome of total joint arthroplasty.

The fructosamine test is a measurement of glycated protein, mainly albumin (the main protein in the blood). When glucose levels in the blood are elevated over a period of time, glucose molecules permanently combine with proteins in the blood in a process called glycation.

Clinical scientists at the Rothman Orthopaedic Institute (Orlando, FL, USA) evaluated in a prospective multi-institutional study preoperative fructosamine and HbA1c levels in patients who had elective total hip arthroplasty (THA) from November 2017 to August 2018. The total patient cohorts included 1,212 patients and patients with and without diabetes were enrolled. The teams assessed fructosamine and HbA1c levels two to three weeks preoperatively. Adverse outcomes, such as PJI, wound complications, readmission and mortality, were assessed at one year postoperatively. A fructosamine level greater than 293 mol/L was defined as inadequate glycemic control and as a predictor for adverse outcomes.

Overall, 960 patients were available for follow-up at 1 year, at which time 3.5% of patients showed inadequate glycemic control based on fructosamine value. This was an unexpected finding as among patients with elevated fructosamine, 85% were unaware they had pre-diabetes and 42% were unaware they had diabetes. The PJI and mortality rates were six times higher in patients with high fructosamine. Readmission rates were five times higher in patients with high fructosamine. Patients with high fructosamine groups had PJI rates of almost 10% and readmission rates of 16%.

Noam Shohat, MD, an orthopedic surgeon and lead author of the study, said, “Fructosamine is inexpensive and readily available marker. It is better reflects the glucose levels prior to surgery. So, it is a better reflector and predictor of outcomes and responds quicker to treatment. For those with levels above 293 mol/L, we strongly encourage you to reconsider the need for surgery.”

The authors concluded that the association between high fructosamine levels and increased risk for PJI was statistically significant after adjustment for age, comorbidities and preoperative HbA1c levels in a regression analysis. The study was presented at the American Association of Hip and Knee Surgeons Annual Hybrid Meeting held November 5-8, 2020 in Dallas, TX, USA.

Related Links:
Rothman Orthopaedic Institute

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.